PUBLISHER: Visiongain Reports Ltd. | PRODUCT CODE: 1422136
PUBLISHER: Visiongain Reports Ltd. | PRODUCT CODE: 1422136
The global Epilepsy Therapeutics market is projected to grow at a CAGR of 8.1% by 2034.
“The Epilepsy Therapeutics Market Report 2024-2034”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
In the ever-evolving field of medical progress, initiatives and innovations in epilepsy treatment are playing a pivotal role in reshaping patient care paradigms. Globally, government-backed endeavors and cutting-edge developments in drugs and treatments are fostering an environment of unprecedented growth in the epilepsy treatment market. A notable initiative occurred when NYU Langone Health secured an $8 million grant from the National Institutes of Health (NIH) in February 2022. The funds are earmarked to develop an innovative implantable monitoring device designed to capture unprecedented data on brain activity during seizures. Led by Dr. Daniel Friedman at NYU Langone's Comprehensive Epilepsy Center, the project addresses the limitations of outdated technology, presenting an opportunity to build an ultrathin device with thousands of measurement contacts. This NIH UG3/UH3-funded initiative involves collaboration with institutions such as New York University's Center for Neural Science, Duke University, the University of Utah, and Blackrock Neurotech.
Designed by Dr. Jonathan Viventi from Duke University, the implant utilizes flexible liquid crystal polymer thermoplastic material and a network of circuits connecting hundreds to thousands of electrodes for high-density sampling of microsignals from extensive brain areas. Successfully tested intraoperatively, the device is poised for clinical use with the capacity for implantation for up to 30 days. As part of the NIH's Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, this collaborative effort places NYU Langone Health at the forefront of transformative advancements in epilepsy care. Clinical trials employing an FDA-approved monitoring implant are expected to commence in 2023, contributing to the growth of the epilepsy treatment market by fostering groundbreaking advancements in laser ablation, high-precision surgeries, and overall improvements in epilepsy treatment outcomes.
A global concern is the accessibility of anti-seizure medication, with many individuals facing difficulties in affording or obtaining multiple medication options, as emphasized in the August 2022 report, 'Survey on the worldwide availability and affordability of anti-seizure medications: Report of the ILAE Task Force on Access to Treatment.' Beyond medication-related challenges, demographic factors contribute significantly to differences in the quality of life and care experiences of individuals. Studies conducted in the United States and North America reveal disparities in seizure control rates and epilepsy remission along racial and ethnic lines. Additionally, there are delays in diagnosis and reduced utilization of epilepsy surgery in specific minority populations.
Furthermore, as highlighted in an article published in December 2022 by NIH, the impact of socioeconomic and racial divides extends to rates of sudden unexpected death in epilepsy (SUDEP). Individuals facing high socioeconomic disadvantage exhibit higher rates of SUDEP, persisting even during periods of decreasing overall SUDEP rates. The identified barriers to care, including medication affordability and access to primary and specialist care, demand comprehensive solutions that extend beyond the healthcare sector. Addressing these issues necessitates not only healthcare interventions but also broader political, economic, and systemic changes. While promising strategies like telehealth services are emerging, sustainable solutions will require coordinated efforts involving individuals, communities, healthcare institutions, and governmental and non-governmental organizations. This underscores the complex and multifaceted nature of the challenges in epilepsy care.
You need to discover how this will impact the Epilepsy Therapeutics Market today, and over the next 10 years:
This report tells you TODAY how the Epilepsy Therapeutics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:
The report also includes profiles and for some of the leading companies in the Epilepsy Therapeutics Market, 2024 to 2034, with a focus on this segment of these companies' operations.
|
|
Overall world revenue for Epilepsy Therapeutics Market, 2024 to 2034 in terms of value the market will surpass US$9,800 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
In summary, our 210+ page report provides you with the following knowledge:
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Epilepsy Therapeutics Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.